|
1
|
Park KC, Crump NT, Louwman N, Krywawych S, Cheong YJ, Vendrell I, Gill EK, Gunadasa-Rohling M, Ford KL, Hauton D, Fournier M, Pires E, Watson L, Roseman G, Holder J, Koschinski A, Carnicer R, Curtis MK, Zaccolo M, Hulikova A, Fischer R, Kramer HB, McCullagh JSO, Trefely S, Milne TA, Swietach P. Disrupted propionate metabolism evokes transcriptional changes in the heart by increasing histone acetylation and propionylation. Nat Cardiovasc Res 2023; 2:1221-1245. [PMID: 38500966 PMCID: PMC7615744 DOI: 10.1038/s44161-023-00365-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 10/15/2023] [Indexed: 03/20/2024]
Abstract
Propiogenic substrates and gut bacteria produce propionate, a post-translational protein modifier. In this study, we used a mouse model of propionic acidaemia (PA) to study how disturbances to propionate metabolism result in histone modifications and changes to gene expression that affect cardiac function. Plasma propionate surrogates were raised in PA mice, but female hearts manifested more profound changes in acyl-CoAs, histone propionylation and acetylation, and transcription. These resulted in moderate diastolic dysfunction with raised diastolic Ca2+, expanded end-systolic ventricular volume and reduced stroke volume. Propionate was traced to histone H3 propionylation and caused increased acetylation genome-wide, including at promoters of Pde9a and Mme, genes related to contractile dysfunction through downscaled cGMP signaling. The less severe phenotype in male hearts correlated with β-alanine buildup. Raising β-alanine in cultured myocytes treated with propionate reduced propionyl-CoA levels, indicating a mechanistic relationship. Thus, we linked perturbed propionate metabolism to epigenetic changes that impact cardiac function.
Collapse
Affiliation(s)
- Kyung Chan Park
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| | - Nicholas T. Crump
- MRC Molecular Haematology Unit, Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
- Present Address: Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK
| | - Niamh Louwman
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| | - Steve Krywawych
- Department of Chemical Pathology, Great Ormond Street Hospital NHS Foundation Trust, London, UK
| | - Yuen Jian Cheong
- Epigenetics & Signalling Programmes, Babraham Institute, Cambridge, UK
| | - Iolanda Vendrell
- Nuffield Department of Medicine, Target Discovery Institute, Oxford, UK
- Nuffield Department of Medicine, Chinese Academy for Medical Sciences Oxford Institute, University of Oxford, Oxford, UK
| | - Eleanor K. Gill
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| | | | - Kerrie L. Ford
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| | - David Hauton
- Department of Chemistry, University of Oxford, Oxford, UK
| | | | | | - Lydia Watson
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| | - Gerald Roseman
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| | - James Holder
- Department of Biochemistry, University of Oxford, Oxford, UK
| | - Andreas Koschinski
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| | - Ricardo Carnicer
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - M. Kate Curtis
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| | - Manuela Zaccolo
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| | - Alzbeta Hulikova
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| | - Roman Fischer
- Nuffield Department of Medicine, Target Discovery Institute, Oxford, UK
- Nuffield Department of Medicine, Chinese Academy for Medical Sciences Oxford Institute, University of Oxford, Oxford, UK
| | - Holger B. Kramer
- MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK
| | | | - Sophie Trefely
- Epigenetics & Signalling Programmes, Babraham Institute, Cambridge, UK
| | - Thomas A. Milne
- MRC Molecular Haematology Unit, Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Pawel Swietach
- Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK
| |
Collapse
|
|
2
|
Pun SH, O’Neill KM, Edgar KS, Gill EK, Moez A, Naderi-Meshkin H, Malla SB, Hookham MB, Alsaggaf M, Madishetti VV, Botezatu B, King W, Brunssen C, Morawietz H, Dunne PD, Brazil DP, Medina RJ, Watson CJ, Grieve DJ. PLAC8-Mediated Activation of NOX4 Signalling Restores Angiogenic Function of Endothelial Colony-Forming Cells in Experimental Hypoxia. Cells 2023; 12:2220. [PMID: 37759443 PMCID: PMC10526321 DOI: 10.3390/cells12182220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 08/28/2023] [Accepted: 09/01/2023] [Indexed: 09/29/2023] Open
Abstract
Ischaemic cardiovascular disease is associated with tissue hypoxia as a significant determinant of angiogenic dysfunction and adverse remodelling. While cord blood-derived endothelial colony-forming cells (CB-ECFCs) hold clear therapeutic potential due to their enhanced angiogenic and proliferative capacity, their impaired functionality within the disease microenvironment represents a major barrier to clinical translation. The aim of this study was to define the specific contribution of NOX4 NADPH oxidase, which we previously reported as a key CB-ECFC regulator, to hypoxia-induced dysfunction and its potential as a therapeutic target. CB-ECFCs exposed to experimental hypoxia demonstrated downregulation of NOX4-mediated reactive oxygen species (ROS) signalling linked with a reduced tube formation, which was partially restored by NOX4 plasmid overexpression. siRNA knockdown of placenta-specific 8 (PLAC8), identified by microarray analysis as an upstream regulator of NOX4 in hypoxic versus normoxic CB-ECFCs, enhanced tube formation, NOX4 expression and hydrogen peroxide generation, and induced several key transcription factors associated with downstream Nrf2 signalling. Taken together, these findings indicated that activation of the PLAC8-NOX4 signalling axis improved CB-ECFC angiogenic functions in experimental hypoxia, highlighting this pathway as a potential target for protecting therapeutic cells against the ischaemic cardiovascular disease microenvironment.
Collapse
Affiliation(s)
- Shun Hay Pun
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Karla M. O’Neill
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Kevin S. Edgar
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Eleanor K. Gill
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Arya Moez
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Hojjat Naderi-Meshkin
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Sudhir B. Malla
- Patrick G Johnston Centre for Cancer Research, Queen’s University, Belfast BT9 7AE, UK; (S.B.M.); (P.D.D.)
| | - Michelle B. Hookham
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Mohammed Alsaggaf
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Vinuthna Vani Madishetti
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Bianca Botezatu
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - William King
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Coy Brunssen
- Division of Vascular Endothelium and Microcirculation, TUD Dresden University of Technology, 01307 Dresden, Germany; (C.B.); (H.M.)
| | - Henning Morawietz
- Division of Vascular Endothelium and Microcirculation, TUD Dresden University of Technology, 01307 Dresden, Germany; (C.B.); (H.M.)
| | - Philip D. Dunne
- Patrick G Johnston Centre for Cancer Research, Queen’s University, Belfast BT9 7AE, UK; (S.B.M.); (P.D.D.)
| | - Derek P. Brazil
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Reinhold J. Medina
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - Chris J. Watson
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| | - David J. Grieve
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast BT9 7AE, UK; (S.H.P.); (K.M.O.); (K.S.E.); (E.K.G.); (A.M.); (H.N.-M.); (M.B.H.); (M.A.); (V.V.M.); (B.B.); (W.K.); (D.P.B.); (R.J.M.); (C.J.W.)
| |
Collapse
|
|
3
|
Walls GM, Ghita M, Queen R, Edgar KS, Gill EK, Kuburas R, Grieve DJ, Watson CJ, McWilliam A, Van Herk M, Williams KJ, Cole AJ, Jain S, Butterworth KT. Spatial Gene Expression Changes in the Mouse Heart After Base-Targeted Irradiation. Int J Radiat Oncol Biol Phys 2023; 115:453-463. [PMID: 35985456 DOI: 10.1016/j.ijrobp.2022.08.031] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 08/03/2022] [Accepted: 08/05/2022] [Indexed: 01/11/2023]
Abstract
PURPOSE Radiation cardiotoxicity (RC) is a clinically significant adverse effect of treatment for patients with thoracic malignancies. Clinical studies in lung cancer have indicated that heart substructures are not uniformly radiosensitive, and that dose to the heart base drives RC. In this study, we aimed to characterize late changes in gene expression using spatial transcriptomics in a mouse model of base regional radiosensitivity. METHODS AND MATERIALS An aged female C57BL/6 mouse was irradiated with 16 Gy delivered to the cranial third of the heart using a 6 × 9 mm parallel opposed beam geometry on a small animal radiation research platform, and a second mouse was sham-irradiated. After echocardiography, whole hearts were collected at 30 weeks for spatial transcriptomic analysis to map gene expression changes occurring in different regions of the partially irradiated heart. Cardiac regions were manually annotated on the capture slides and the gene expression profiles compared across different regions. RESULTS Ejection fraction was reduced at 30 weeks after a 16 Gy irradiation to the heart base, compared with the sham-irradiated controls. There were markedly more significant gene expression changes within the irradiated regions compared with nonirradiated regions. Variation was observed in the transcriptomic effects of radiation on different cardiac base structures (eg, between the right atrium [n = 86 dysregulated genes], left atrium [n = 96 dysregulated genes], and the vasculature [n = 129 dysregulated genes]). Disrupted biological processes spanned extracellular matrix as well as circulatory, neuronal, and contractility activities. CONCLUSIONS This is the first study to report spatially resolved gene expression changes in irradiated tissues. Examination of the regional radiation response in the heart can help to further our understanding of the cardiac base's radiosensitivity and support the development of actionable targets for pharmacologic intervention and biologically relevant dose constraints.
Collapse
Affiliation(s)
- Gerard M Walls
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland; Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, Northern Ireland.
| | - Mihaela Ghita
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland
| | - Rachel Queen
- Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, England
| | - Kevin S Edgar
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland
| | - Eleanor K Gill
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, England
| | - Refik Kuburas
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland
| | - David J Grieve
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland
| | - Chris J Watson
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland
| | - Alan McWilliam
- Division of Cancer Sciences, University of Manchester, Oglesby Building, Manchester, England; Department of Radiation Therapy Related Research, The Christie Foundation Trust, Manchester, England
| | - Marcel Van Herk
- Division of Cancer Sciences, University of Manchester, Oglesby Building, Manchester, England; Department of Radiation Therapy Related Research, The Christie Foundation Trust, Manchester, England
| | - Kaye J Williams
- Division of Pharmacy and Optometry, School of Health Science, Faculty of Biology Medicine and Health, University of Manchester, Manchester, England
| | - Aidan J Cole
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland; Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, Northern Ireland
| | - Suneil Jain
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland; Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, Northern Ireland
| | - Karl T Butterworth
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland
| |
Collapse
|
|
4
|
Ghita M, Gill EK, Walls GM, Edgar KS, McMahon SJ, Osorio EV, Bergom C, Grieve DJ, Watson CJ, McWilliam A, Aznar M, van Herk M, Williams KJ, Butterworth KT. Cardiac sub-volume targeting demonstrates regional radiosensitivity in the mouse heart. Radiother Oncol 2020; 152:216-221. [PMID: 32663535 PMCID: PMC10181791 DOI: 10.1016/j.radonc.2020.07.016] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Revised: 06/26/2020] [Accepted: 07/07/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND PURPOSE Radiation-induced cardiac toxicity (RICT) remains one of the most critical dose limiting constraints in radiotherapy. Recent studies have shown higher doses to the base of the heart are associated with worse overall survival in lung cancer patients receiving radiotherapy. This work aimed to investigate the impact of sub-volume heart irradiation in a mouse model using small animal image-guided radiotherapy. MATERIALS AND METHODS C57BL/6 mice were irradiated with a single fraction of 16 Gy to the base, middle or apex of the heart using a small animal radiotherapy research platform. Cone beam CT and echocardiography were performed at baseline and at 10 week intervals until 50 weeks post-treatment. Structural and functional parameters were correlated with mean heart dose (MHD) and volume of heart receiving 5 Gy (V5). RESULTS All irradiated mice showed a time dependent increase in left ventricle wall thickness in diastole of ~0.2 mm detected at 10 weeks post-treatment, with the most significant and persistent changes occurring in the heart base-irradiated animals. Similarly, statistically different functional effects (p < 0.01) were observed in base-irradiated animals which showed the most significant decreases compared to controls. The observed functional changes did not correlate with MHD and V5 (R2 < 0.1), indicating that whole heart dosimetry parameters do not predict physiological changes resulting from cardiac sub-volume irradiation. CONCLUSIONS This is the first report demonstrating the structural and functional consequences of sub-volume targeting in the mouse heart and reverse translates clinical observations indicating the heart base as a critical radiosensitive region.
Collapse
Affiliation(s)
- Mihaela Ghita
- Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, United Kingdom
| | - Eleanor K Gill
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, United Kingdom
| | - Gerard M Walls
- Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, United Kingdom
| | - Kevin S Edgar
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, United Kingdom
| | - Stephen J McMahon
- Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, United Kingdom
| | - Eliana Vasquez Osorio
- Department of Radiotherapy Related Research, University of Manchester, United Kingdom
| | - Carmen Bergom
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, United States; Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA
| | - David J Grieve
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, United Kingdom
| | - Chris J Watson
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, United Kingdom
| | - Alan McWilliam
- Department of Radiotherapy Related Research, University of Manchester, United Kingdom
| | - Marianne Aznar
- Department of Radiotherapy Related Research, University of Manchester, United Kingdom
| | - Marcel van Herk
- Department of Radiotherapy Related Research, University of Manchester, United Kingdom
| | - Kaye J Williams
- Division of Pharmacy and Optometry, University of Manchester, United Kingdom
| | - Karl T Butterworth
- Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, United Kingdom.
| |
Collapse
|
|
5
|
O'Neill KM, Campbell DC, Edgar KS, Gill EK, Moez A, McLoughlin KJ, O'Neill CL, Dellett M, Hargey CJ, Abudalo RA, O'Hare M, Doyle P, Toh T, Khoo J, Wong J, McCrudden CM, Meloni M, Brunssen C, Morawietz H, Yoder MC, McDonald DM, Watson CJ, Stitt AW, Margariti A, Medina RJ, Grieve DJ. NOX4 is a major regulator of cord blood-derived endothelial colony-forming cells which promotes post-ischaemic revascularization. Cardiovasc Res 2020; 116:393-405. [PMID: 30937452 DOI: 10.1093/cvr/cvz090] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 02/19/2019] [Accepted: 03/29/2019] [Indexed: 02/06/2023] Open
Abstract
AIMS Cord blood-derived endothelial colony-forming cells (CB-ECFCs) are a defined progenitor population with established roles in vascular homeostasis and angiogenesis, which possess low immunogenicity and high potential for allogeneic therapy and are highly sensitive to regulation by reactive oxygen species (ROS). The aim of this study was to define the precise role of the major ROS-producing enzyme, NOX4 NADPH oxidase, in CB-ECFC vasoreparative function. METHODS AND RESULTS In vitro CB-ECFC migration (scratch-wound assay) and tubulogenesis (tube length, branch number) was enhanced by phorbol 12-myristate 13-acetate (PMA)-induced superoxide in a NOX-dependent manner. CB-ECFCs highly-expressed NOX4, which was further induced by PMA, whilst NOX4 siRNA and plasmid overexpression reduced and potentiated in vitro function, respectively. Increased ROS generation in NOX4-overexpressing CB-ECFCs (DCF fluorescence, flow cytometry) was specifically reduced by superoxide dismutase, highlighting induction of ROS-specific signalling. Laser Doppler imaging of mouse ischaemic hindlimbs at 7 days indicated that NOX4-knockdown CB-ECFCs inhibited blood flow recovery, which was enhanced by NOX4-overexpressing CB-ECFCs. Tissue analysis at 14 days revealed consistent alterations in vascular density (lectin expression) and eNOS protein despite clearance of injected CB-ECFCs, suggesting NOX4-mediated modulation of host tissue. Indeed, proteome array analysis indicated that NOX4-knockdown CB-ECFCs largely suppressed tissue angiogenesis, whilst NOX4-overexpressing CB-ECFCs up-regulated a number of pro-angiogenic factors specifically-linked with eNOS signalling, in parallel with equivalent modulation of NOX-dependent ROS generation, suggesting that CB-ECFC NOX4 signalling may promote host vascular repair. CONCLUSION Taken together, these findings indicate a key role for NOX4 in CB-ECFCs, thereby highlighting its potential as a target for enhancing their reparative function through therapeutic priming to support creation of a pro-reparative microenvironment and effective post-ischaemic revascularization.
Collapse
Affiliation(s)
- Karla M O'Neill
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - David C Campbell
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Kevin S Edgar
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Eleanor K Gill
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Arya Moez
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Kiran J McLoughlin
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Christina L O'Neill
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Margaret Dellett
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Ciarán J Hargey
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Rawan A Abudalo
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Michael O'Hare
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Philip Doyle
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Tinrui Toh
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Joshua Khoo
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - June Wong
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Cian M McCrudden
- School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK
| | | | - Coy Brunssen
- Division of Vascular Endothelium and Microcirculation, Department of Medicine III, Medical Faculty and University Clinics Carl Gustav Carus, Technische Universität Dresden, D-01307 Dresden, Germany
| | - Henning Morawietz
- Division of Vascular Endothelium and Microcirculation, Department of Medicine III, Medical Faculty and University Clinics Carl Gustav Carus, Technische Universität Dresden, D-01307 Dresden, Germany
| | - Mervin C Yoder
- Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Denise M McDonald
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Chris J Watson
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Alan W Stitt
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Andriana Margariti
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Reinhold J Medina
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - David J Grieve
- Centre for Experimental Medicine, Wellcome-Wolfson Institute, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| |
Collapse
|
|
6
|
Wilson AJ, Gill EK, Abudalo RA, Edgar KS, Watson CJ, Grieve DJ. Reactive oxygen species signalling in the diabetic heart: emerging prospect for therapeutic targeting. Heart 2017; 104:293-299. [DOI: 10.1136/heartjnl-2017-311448] [Citation(s) in RCA: 113] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Revised: 08/24/2017] [Accepted: 08/24/2017] [Indexed: 01/27/2023] Open
Abstract
Despite being first described 45 years ago, the existence of a distinct diabetic cardiomyopathy remains controversial. Nonetheless, it is widely accepted that the diabetic heart undergoes characteristic structural and functional changes in the absence of ischaemia and hypertension, which are independently linked to heart failure progression and are likely to underlie enhanced susceptibility to stress. A prominent feature is marked collagen accumulation linked with inflammation and extensive extracellular matrix changes, which appears to be the main factor underlying cardiac stiffness and subclinical diastolic dysfunction, estimated to occur in as many as 75% of optimally controlled diabetics. Whether this characteristic remodelling phenotype is primarily driven by microvascular dysfunction or alterations in cardiomyocyte metabolism remains unclear. Although hyperglycaemia regulates multiple pathways in the diabetic heart, increased reactive oxygen species (ROS) generation is thought to represent a central mechanism underlying associated adverse remodelling. Indeed, experimental and clinical diabetes are linked with oxidative stress which plays a key role in cardiomyopathy, while key processes underlying diabetic cardiac remodelling, such as inflammation, angiogenesis, cardiomyocyte hypertrophy and apoptosis, fibrosis and contractile dysfunction, are redox sensitive. This review will explore the relative contributions of the major ROS sources (dysfunctional nitric oxide synthase, mitochondria, xanthine oxidase, nicotinamide adenine dinucleotide phosphate oxidases) in the diabetic heart and the potential for therapeutic targeting of ROS signalling using novel pharmacological and non-pharmacological approaches to modify specific aspects of the remodelling phenotype in order to prevent and/or delay heart failure development and progression.
Collapse
|
|
7
|
Gill EK. Report to the Master Plan Sub-committee on Educational Programs for the Health Professions. Nursing 1973; 45:8-9. [PMID: 4486343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
|
8
|
|